Sign in

BDTB on OTC

Bodhi Tree Biotechnology Inc

American management consulting services company based in Danville1

In its 2025 annual report the company says: “We are an early-stage consulting company focused on providing plant-based menu design, recipe development, and vegetarian diet consulting services. Our executive office is located in Danville, California. We create and develop new recipes and menus to address emerging market trends and the growing demand for healthy plant-based options.”4 Its shares trade on OTC under the symbol BDTB.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$17.0KRevenue, fiscal 20252
-$149.7KNet income, fiscal 20252

Compare with Wenyuan Group Corp., Hestia Insight Inc. or SATIVUS TECH CORP., or pick any stock.

  • TickerBDTB on OTC1
  • IndustryServices-Management Consulting Services1
  • HeadquartersDanville, California1
  • Incorporated inDE3
  • Business address4125 Blackhawk Plaza Circle, Suite 172, Danville, Ca 945063
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Bodhi Tree Biotechnology Inc. (“us,” “our,” “we,” or the “Company”) was incorporated in the State of Delaware on December 12, 2023. We are an early-stage consulting company focused on providing plant-based menu design, recipe development, and vegetarian diet consulting services. Our executive office is located in Danville, California.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-868.3%Operating margin2
-880.4%Net margin2
-125.6%Return on equity2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Other costs88¢$14.9K
  • Income tax12¢$2.0K

Out of $17.0K in revenue.2 The company lost money this year.

Financial statements

Every line of the income statement as filed: the last 1 fiscal year, latest first.2

Period ending2025-09-30
Service revenue$17.0K
General and administrative expenses$164.6K
Loss from operation-$147.6K
Loss before provision for income taxes-$147.6K
Interest income$2
Total other income$2
Loss before income taxes-$147.6K
Provision for income taxes$2.0K
Net Loss-$149.7K
Basic loss per common share-$0.01
Diluted loss per common share-$0.01
Basic weighted average number of common shares used in per share25.4M shares
Diluted weighted average number of common shares used in per share25.4M shares

Compare Bodhi Tree Biotechnology Inc with another company

What it owns

What Bodhi Tree Biotechnology Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

We do not own any real property. We sublease office space from BEEC Inc. located at 4125 Blackhawk Plaza Circle, Suite 172, Danville, California. The sublease was renewed for a one-year term beginning June 1, 2025 and ending May 31, 2026, and requires monthly rent payments of $900. This office space is adequate for our current administrative needs.

Item 2 of the 10-K filed Dec 29, 2025.4

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICERXiaohang Wang named Jun 5, 20258
  • DirectorJonathan Ginsberg named Jun 5, 20258
  • EXECUTIVE CHAIRMAN AND DIRECTORJuan Ye named Jun 5, 20258

Timeline

  1. Jun 6, 20258-K Other events9

Filings

26 filings to the SEC since October 2021: 1 annual reports, 6 quarterly reports, 1 major events, 2 private raises, 16 other. The latest 20:

  1. Aug 14, 202610-Q EDGAR
  2. May 14, 202610-Q EDGAR
  3. Feb 13, 202610-Q EDGAR
  4. Dec 29, 202510-K EDGAR
  5. Aug 12, 202510-Q EDGAR
  6. Jul 28, 202510-Q/A EDGAR
  7. Jun 6, 20258-K EDGAR
  8. Jun 5, 2025D/A EDGAR
  9. May 20, 202510-Q EDGAR
  10. May 14, 2025NT 10-Q EDGAR
  11. Apr 15, 2025D EDGAR
  12. Mar 4, 2025424B3 EDGAR
  13. Mar 3, 2025EFFECT EDGAR
  14. Feb 27, 2025CORRESP EDGAR
  15. Feb 21, 2025S-1/A EDGAR
  16. Feb 4, 2025S-1 EDGAR
  17. Dec 27, 2024CORRESP EDGAR
  18. Dec 27, 2024DRS/A EDGAR
  19. Dec 20, 2024UPLOAD EDGAR
  20. Dec 16, 2024DRS/A EDGAR

The 26 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$48.2K 2024–2024
Money received by yearMoney received by year, 2024–2024: $48.2K in all. Private raises (Form D) $48.2K.$0$20K$40K$60K2024 · Private raises (Form D): $48.2K2024
Figures by year
YearPrivate raises (Form D)Total
2024$48.2K$48.2K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Mar 15, 2024Raised $48,200 in a private offering of equity8 Form D: 32 investors so far Form D

SEC filer profile

How Bodhi Tree Biotechnology Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBodhi Tree Biotechnology Inc1
  • CIK0002041531
  • Employer ID (EIN)93-49084494
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsSeptember 301
  • Industry code (SIC)8742 Services-Management Consulting Services1
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
  • Business address4125 Blackhawk Plaza Circle, Suite 172, Danville, CA 945061
  • Phone(925)406-45281
  • Shares outstanding25,441,042 as of Aug 14, 20267
  • Public float$0 as of Mar 31, 20262
  • AuditorSimon & Edward, LLP, Rowland Heights, CA PCAOB ID 2485; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceOct 21, 20241
  • Filings26 in all: 10-Q (5), CORRESP (4), DRS/A (3), UPLOAD (3), 10-K (1), 10-Q/A (1), 424B3 (1), 8-K (1)1
    All 15 form types

    D (1), D/A (1), DRS (1), EFFECT (1), NT 10-Q (1), S-1 (1), S-1/A (1)

  • Latest filingsAnnual report (10-K) Dec 29, 2025
    Quarterly report (10-Q) Aug 14, 2026
    Latest 8-K (8-K) Jun 6, 2025

Risk factors and legal proceedings

The risks Bodhi Tree Biotechnology Inc names in Item 1A of its 10-K filed Dec 29, 2025: 39 risks under these headings, as written.4

  • We have limited operating history and it is difficult to evaluate our potential for business success.
  • Because the Company is an “emerging growth company,” the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies.”
  • We may have difficulty raising additional capital, which could deprive us of necessary resources.
  • Our management team lacks experience in managing a public company and complying with laws applicable to such a company, the failure of which may adversely affect our business, financial conditions and results of operations.
  • We are dependent upon our only key executive who is not bound by any employment agreement nor does the Company maintain director and officers (“D&O”) liability insurance for him.
  • We may be forced to curtail or discontinue operations if we are unable to obtain, on commercially acceptable terms, additional capital that we may require from time to time in the future to finance our operations and growth.
  • We face intense competition and could lose market share to our competitors, which could adversely affect our business, operating results and financial condition.
  • Failure to protect our intellectual property could adversely affect our business.
  • We may not be able to develop, maintain or enhance our brand.
  • We will need to achieve commercial acceptance of our services to generate revenues and achieve profitability.
  • We may not be successful in introducing new products and services or enhancing our existing products and services.
  • Consumer preferences for our products and services are difficult to predict and may change, and, if we are unable to respond quickly to new trends, our business may be adversely affected.
The other 27 risks
  • Any failure by us to properly price our products and services could ‎have ‎a material adverse effect on our financial condition and results of operations.
  • Our success depends on the continuing efforts of our senior management team and other key personnel and our business may be harmed if we lose their services.
  • If we are unable to build a sufficient distribution network to meet increasing demand of our product and services, our ability to execute on our business plan as outlined in this report will be impaired.
  • We may encounter disputes from time to time relating to the use of third-party intellectual properties.
  • We may fail to adequately protect our intellectual property rights, and we may be exposed to intellectual property infringement claims by third parties.
  • Adverse litigation judgments or settlements resulting from legal or arbitral proceedings in which we may be involved could expose us to monetary damages, equitable restraints or limit our ability to operate our business.
  • Our business may be materially adversely affected by new outbreaks, or continuation of any existing outbreaks, of any infectious disease and other events.
  • Our geographic focus makes us particularly vulnerable to economic and other events and trends in the United States.
  • Our business could be negatively impacted by changes in the U.S. political environment.
  • Changes in existing laws or regulations, or the adoption of new laws or regulations may increase costs and otherwise adversely affect our business, results of operations and financial condition.
  • We have limited insurance coverage with respect to our business and operations.
  • Our employees may engage in misconduct or other improper activities.
  • Our inability to renew existing leases on favorable terms may adversely affect our results of operations.
  • Risks Relating to Our Common Stock
  • We have not paid dividends and do not expect to do so in the foreseeable future.
  • Our common stock is subject to the “penny stock” rules of the SEC and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.
  • You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against us or our management named in the report based on foreign laws.
  • We depend on our information technology systems, and any failure of these systems could harm our business.
  • There is currently no active trading market for our shares of common stock on the OTCQB. You may not be able to sell your shares of common stock if you require funds.
  • If we fail to remain current on our SEC reporting requirements or fail to comply with the continuing eligibility of OTCQB, we could be removed from the OTCQB marketplace, which would limit the ability of broker-dealers to sell our securities in the secondary market.
  • The sales practice requirements of FINRA may limit a stockholder’s ability to buy and sell our common stock.
  • Issuance of stock to fund our operations may dilute your investment and reduce your equity interest.
  • Provisions of our charter documents or Delaware law could delay or prevent an acquisition of the Company, even if such an acquisition would be beneficial to our stockholders, which could make it more difficult for you to change management.
  • Risks Related to Our Common Stock
  • If an active trading market for our common stock develops, the market price of our shares may be volatile and could fluctuate significantly due to factors beyond our control.
  • If securities or industry analysts do not publish research or reports about our business, or if they adversely change their recommendations regarding our common stock, the market price for our common stock and trading volume could decline.
  • Negative publicity may harm our brand and reputation and have a material adverse effect on business.
  • We will incur increased costs as a result of being a public company, particularly after we cease to qualify as an “emerging growth company.”
  • If we fail to establish and maintain proper internal financial reporting controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.

Legal proceedings

We are not currently involved in any legal proceedings, and no director, officer, or significant shareholder is a party to any legal proceedings that are adverse to us or that would materially affect our business or financial condition.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
    SEC EDGAROther events